These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10935673)

  • 21. [New oral drugs for the treatment of congestive heart failure].
    Hayashida W; Kumada T; Kawai C
    Nihon Rinsho; 1992 Feb; 50(2):413-9. PubMed ID: 1319514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
    Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of intravenous inotropic therapy in the home.
    McCloskey WW
    Am J Health Syst Pharm; 1998 May; 55(9):930-5; quiz 953-4. PubMed ID: 9588252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction.
    Cody RJ
    J Am Coll Cardiol; 1988 Aug; 12(2):559-61. PubMed ID: 3392348
    [No Abstract]   [Full Text] [Related]  

  • 25. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.
    Moertl D; Berger R; Huelsmann M; Bojic A; Pacher R
    Eur J Heart Fail; 2005 Dec; 7(7):1156-63. PubMed ID: 16084762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit.
    Charisopoulou D; Leaver N; Banner NR
    Angiology; 2014 Apr; 65(4):343-9. PubMed ID: 23620310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostaglandin E1--bridge to cardiac transplantation. Technique, dosage, results.
    Pacher R; Stanek B; Hülsmann M; Berger R; Siegel A; Daneschvar H; Rödler S; Frey B; Grimm M; Laufer G
    Eur Heart J; 1997 Feb; 18(2):318-29. PubMed ID: 9043849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Worsening heart failure in 'real-world' clinical practice: predictors and prognostic impact.
    AlFaleh H; Elasfar AA; Ullah A; AlHabib KF; Hersi A; Mimish L; Almasood A; Al Ghamdi S; Ghabashi A; Malik A; Hussein GA; Al-Murayeh M; Abuosa A; Al Habeeb W; Kashour T
    Eur J Heart Fail; 2017 Aug; 19(8):987-995. PubMed ID: 27071748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heart failure treated with low-dose milrinone in a full-term newborn.
    Sebková S; Tomek V; Zemanová P; Janota J
    Prague Med Rep; 2012; 113(1):58-65. PubMed ID: 22373807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Calcium sensitizer agents in heart failure therapy].
    Iwama Y; Takagi A
    Nihon Rinsho; 2007 May; 65 Suppl 5():61-5. PubMed ID: 17571366
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.
    Dei Cas L; Metra M; Nodari S; Visioli O
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S111-7. PubMed ID: 2483436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacology of inodilators.
    Dei Cas L; Metra M; Visioli O
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S60-71. PubMed ID: 2483442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Is heart rate reduction beneficial to patients with heart insufficiency? Focus on beta-blockade].
    Henriksen OM; Gadsbøll N
    Ugeskr Laeger; 2002 Jan; 164(5):615-9. PubMed ID: 11871210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The case against outpatient parenteral inotropic therapy for advanced heart failure.
    Rapezzi C; Bracchetti G; Branzi A; Magnani B
    J Heart Lung Transplant; 2000 Aug; 19(8 Suppl):S58-63. PubMed ID: 11016489
    [No Abstract]   [Full Text] [Related]  

  • 35. Predictors of clinical outcome in advanced heart failure patients on continuous intravenous milrinone therapy.
    Bhat G
    ASAIO J; 2006; 52(6):677-81. PubMed ID: 17117058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Choice for the treatment of congestive heart failure].
    J Cardiol Suppl; 1989; 20():53-6. PubMed ID: 2557870
    [No Abstract]   [Full Text] [Related]  

  • 37. Acceptance of a pump-driven infusion therapy with prostaglandin E1 as a bridge to heart transplantation.
    Daneschvar H; Pacher R; Rödler S; Stanek B; Hülsmann M; Grimm M; Laufer G; Wolner E; Bunzel B
    Wien Klin Wochenschr; 1996; 108(16):510-4. PubMed ID: 8840497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hemodynamic effects of milrinone on patients with chronic congestive heart failure: a multicenter study. Cooperative Group for Phase II Clinical Trial of Milrinone].
    Zhonghua Nei Ke Za Zhi; 1995 Sep; 34(9):599-602. PubMed ID: 8697925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Old and new intravenous inotropic agents in the treatment of advanced heart failure.
    Metra M; Bettari L; Carubelli V; Cas LD
    Prog Cardiovasc Dis; 2011; 54(2):97-106. PubMed ID: 21875509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of heart failure in children].
    Pipitone S; Manetti A
    G Ital Cardiol; 1995 Nov; 25(11):1485-90. PubMed ID: 8682250
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.